Lilly olomorasib ESMO 2026 results show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer. The data cover olomorasib with pembrolizumab, with or without chemotherapy. Lilly expects first randomized Phase 3 SUNRAY-01 data in the first half of 2027.
Johnson & Johnson will present more than 25 solid tumor abstracts at ESMO 2026, led by the first JNJ-6143 RIPTAC readout in prostate cancer, new RYBREVANT FASPRO head and neck data and ERLEADA PROTEUS findings.
Abbott Q3 2026 Results show net sales of $13.013 billion, up 14.5% reported and 7.0% comparable, with adjusted EPS of $1.42 and full-year EPS guidance tightened to $5.50 to $5.55.
Samsung Biologics Q3 2026 Results show revenue of KRW 1,490 billion and operating profit of KRW 640 billion. Plant 5 ramp-up and the Rockville site contributed, and the company raised its 2026 revenue growth guidance to 20%.
ohnson & Johnson Q3 2026 Results: sales rose 5.9% to $25.4B, adjusted EPS hit $2.59 and 2026 guidance rose to $11.10 adjusted EPS at the midpoint.
AbbVie has presented detailed Phase 1 data for ABBV-295 at EASD 2026, demonstrating meaningful body weight reduction, favorable tolerability and an approximately 11–12-day half-life. The investigational long-acting amylin analog is advancing toward Phase 2 development for chronic weight management, with potential dosing intervals extending beyond weekly administration.
Novo Nordisk presented CagriSema EASD 2026 data showing changed brain responses to food cues, reduced ‘food noise’, less fat around abdominal organs and preliminary bone reassurance in adults with obesity or type 2 diabetes.
Charles River Laboratories (NYSE: CRL) posted Q2 2026 revenue of $1.00 billion and non-GAAP EPS of $3.02, then raised full-year guidance on strengthening DSA demand and Manufacturing outperformance, even as GAAP results absorbed a one-time loss from its CDMO and Cell Solutions divestiture.
Eli Lilly Q2 2026 earnings rose 48% to $23.0 billion, driven by Mounjaro and Zepbound demand, as the company raised full-year revenue and EPS guidance and advanced its obesity, oncology, and immunology pipeline through regulatory wins and four completed acquisitions.
Pfizer Q2 2026 Earnings report $15.03B in revenue, fueled by an 18% operational surge in non-COVID biopharmaceuticals including Padcev and Vyndaqel.
